查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703293

藥物基因組學技術市場－全球產業規模、佔有率、趨勢、機會及預測，依治療領域、技術、地區及競爭情況細分，2020-2030 年

Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapeutic Area, By Technology, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球藥物基因組學技術市場價值為 76 億美元，預計將經歷強勁成長，到 2030 年達到重要里程碑，預測期內的年複合成長率(CAGR) 為 8.45%。隨著醫療保健領域的不斷發展，個人化醫療對於改善患者治療效果和減少藥物不良反應變得越來越重要。處於這一轉變前沿的是藥物基因組學（PGx），這是一個變革性領域，它能夠根據個人的基因特徵量身定做藥物療法。

市場概覽
預測期 2026-2030
2024年市場規模 76億美元
2030年市場規模 123.9億美元
2025-2030 年複合年成長率 8.45%
成長最快的領域 腫瘤學
最大的市場 北美洲

藥物基因組學是基因組學的一個專業領域，研究基因變異如何影響藥物代謝和反應。鑑於每個人的 DNA 都是獨一無二的，這種方法有助於識別預測患者對特定藥物的反應的遺傳標記。因此，藥物基因組學使醫療保健提供者能夠客製化治療方案以實現最大有效性和安全性，從通用治療模式轉向精準醫療。

關鍵市場促進因素

慢性病盛行率不斷上升

主要市場挑戰

數據複雜性和整合障礙

主要市場趨勢

技術進步推動市場發展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：藥物基因體學技術市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療領域（腫瘤學（肺癌、乳癌、大腸癌、子宮頸癌等）、神經系統疾病、心血管疾病、免疫系統疾病、傳染病等）
    • 按技術（PCR、原位雜合技術、免疫組織化學、定序、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美藥物基因體學技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲藥物基因體學技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太藥物基因體學技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美藥物基因體學技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲藥物基因組學技術市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球藥物基因組學技術市場：SWOT 分析

第 14 章：競爭格局

  • QIAGEN NV
  • GE HealthCare,
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH,
  • Pfizer Inc..

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16370

Global Pharmacogenomics Technology market was valued at USD 7.60 billion in 2024 and is projected to experience robust growth, reaching significant milestones by 2030 with a compound annual growth rate (CAGR) of 8.45% over the forecast period. As the healthcare landscape continues to evolve, personalized medicine is becoming central to enhancing patient outcomes and minimizing adverse drug reactions. At the forefront of this shift is pharmacogenomics (PGx), a transformative field that enables the customization of drug therapies based on an individual's genetic profile.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.60 Billion
Market Size 2030USD 12.39 Billion
CAGR 2025-20308.45%
Fastest Growing SegmentOncology
Largest MarketNorth America

Pharmacogenomics, a specialized area within genomics, studies how genetic variations influence drug metabolism and response. Given that every individual's DNA is unique, this approach facilitates the identification of genetic markers that predict how patients will respond to specific medications. As a result, pharmacogenomics allows healthcare providers to tailor treatments for maximum effectiveness and safety, moving away from generalized treatment models toward precision medicine.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases globally is a primary catalyst for the growth of the pharmacogenomics technology market. Conditions such as cancer, cardiovascular disease, diabetes, and chronic respiratory disorders remain leading causes of mortality, collectively responsible for over 41 million deaths annually. Additionally, approximately one in three adults worldwide live with multiple chronic conditions, necessitating long-term and highly personalized treatment plans.

In 2022 alone, there were an estimated 20 million new cancer cases and 9.7 million related deaths, while 53.5 million individuals were within five years of a cancer diagnosis. These figures highlight the growing burden of chronic illness and the need for more effective and individualized therapeutic approaches.

Traditional treatment models often rely on trial-and-error prescribing, which can result in suboptimal outcomes and increased healthcare costs. Pharmacogenomics offers a solution by matching patients with the most appropriate medications based on their genetic makeup, thereby improving therapeutic efficacy and reducing adverse drug events. The economic implications are also significant-pharmacogenomics supports cost containment by decreasing the use of ineffective treatments and reducing hospitalizations due to drug-related complications. This makes it an attractive proposition for both public health systems and private payers, fueling broader industry adoption.

Key Market Challenges

Complexity of Data and Integration Barriers

One of the principal challenges in the pharmacogenomics sector lies in managing and integrating the vast amounts of complex data generated through genomic sequencing and drug response studies. Accurate prediction of drug efficacy and safety hinges on the effective analysis of these datasets, which requires sophisticated bioinformatics tools and specialized expertise. However, such capabilities are not uniformly distributed across global healthcare systems, creating disparities in implementation and limiting market penetration in certain regions.

Key Market Trends

Advancements in Technology Driving Market Evolution

Technological innovation continues to be a major growth enabler for the pharmacogenomics industry. High-throughput techniques such as next-generation sequencing (NGS) have revolutionized the field by enabling rapid, cost-effective analysis of entire genomes or targeted gene regions. NGS has dramatically improved the accuracy and efficiency of detecting clinically relevant genetic variants, expanding the potential for personalized drug therapy.

The proliferation of genomic data generated through NGS has necessitated the adoption of advanced analytical solutions. Machine learning and artificial intelligence (AI) have emerged as vital tools for interpreting complex datasets, identifying patterns, and predicting individual drug responses. These technologies are facilitating more informed decision-making for clinicians and accelerating the integration of pharmacogenomics into routine clinical practice.

Key Market Players

  • QIAGEN N.V.
  • GE HealthCare,
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Leica Biosystems Nussloch GmBH,
  • Pfizer Inc.

Report Scope:

In this report, the Global Pharmacogenomics Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmacogenomics Technology Market, By Therapeutics Area:

  • Oncology
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technology Market, By Technology:

  • PCR
  • In-situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmacogenomics Technology Market.

Available Customizations:

Global Pharmacogenomics Technology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pharmacogenomics Technology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases, Others)
    • 5.2.2. By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Pharmacogenomics Technology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutics Area
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmacogenomics Technology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutics Area
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Pharmacogenomics Technology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutics Area
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Pharmacogenomics Technology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutics Area
        • 6.3.3.2.2. By Technology

7. Europe Pharmacogenomics Technology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutics Area
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmacogenomics Technology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutics Area
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Pharmacogenomics Technology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutics Area
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Pharmacogenomics Technology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutics Area
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Pharmacogenomics Technology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutics Area
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Pharmacogenomics Technology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutics Area
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Pharmacogenomics Technology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutics Area
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pharmacogenomics Technology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutics Area
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Pharmacogenomics Technology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutics Area
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Pharmacogenomics Technology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutics Area
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Pharmacogenomics Technology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutics Area
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Pharmacogenomics Technology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutics Area
        • 8.3.5.2.2. By Technology

9. South America Pharmacogenomics Technology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutics Area
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pharmacogenomics Technology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutics Area
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Pharmacogenomics Technology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutics Area
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Pharmacogenomics Technology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutics Area
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Pharmacogenomics Technology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutics Area
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pharmacogenomics Technology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutics Area
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Pharmacogenomics Technology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutics Area
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Pharmacogenomics Technology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutics Area
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Pharmacogenomics Technology Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. QIAGEN N.V.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. GE HealthCare,
  • 14.3. Agilent Technologies, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. FOUNDATION MEDICINE, INC.
  • 14.6. Thermo Fisher Scientific Inc.
  • 14.7. Leica Biosystems Nussloch GmBH,
  • 14.8. Pfizer Inc..

15. Strategic Recommendations

16. About Us & Disclaimer